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1. Introduction
1.1. Epidemiology – Clinical presentation-screening
Colorectal cancer (CRC) is a common and lethal disease. The risk of developing CRC is
influenced by both environmental and genetic factors. Colorectal cancer is the third most
common cancer worldwide. Clinical symptoms develop late in the course of the disease, and
precursor lesions (adenomas) can be easily detected and removed. The disease is a candidate
for early detection and prevention by screening. The epidemiology of CRC and risk factors for
its development will be discussed here.
Epidemiology — CRC incidence and mortality rates vary markedly around the world [1].
Globally, CRC is the third most commonly diagnosed cancer in males and the second in
females, with over 1.2 million new cases and 608,700 deaths estimated to have occurred in
2008.Incidence and mortality rates are substantially higher in males than in females [2]. It is
the fourth most common cause of cancer death after lung, stomach, and liver cancer. It is more
common in developed than developing countries.
In the United States, both the incidence and mortality have been slowly but steadily decreasing.
Annually approximately 143,460 new cases of large bowel cancer are diagnosed, of which
103,170 are colon and the remainder rectal cancers. Annually, approximately 51,690 Americans
die of CRC, accounting for approximately 9 percent of all cancer deaths [6].
Incidence — There is significant geographical variation in age-standardized and cumulative,
0-74 year incidence and mortality rates. Globally, the incidence of CRC varies over 10-fold.
The highest incidence rates are in Australia and New Zealand, Europe and North America,
and the lowest rates are found in Africa and South-Central Asia [5]. The highest incidence rate
of CRC is estimated in the Czech Republic [39-42]. These geographic differences appear to be
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attributable to differences in dietary and environmental exposures that are imposed upon a
background of genetically determined susceptibility.
In Europe, the incidence of colorectal cancer is increasing, particularly in Southern and Eastern
Europe, where rates were originally lower than in Western Europe [7]. In the USA, incidence
rose until the mid-1980s but in the last two decades the rates have fallen for both men and
women. Countries that have had a rapid ‘westernization’ of diet, such as Japan, have seen a
rapid increase in incidence of colorectal cancer. Consumption of meat and dairy products in
Japan increased tenfold between the 1950s and 1990s.
Figure 1. Age-adjusted colorectal cancer incidence and death rates in the United States 1975–2006.
Colonoscopy and Colorectal Cancer Screening - Future Directions4
Colorectal cancer (CRC) is a disease with a major worldwide burden. The worldwide inci‐
dence of CRC is increasing. In 1975, the worldwide incidence of CRC was only 500,000.In
western countries, some of the increase is due to the aging of the population. However, in
countries with a low baseline rate of CRC, the incidence is increasing even after age-adjust‐
ment. Prior to 1985, the age-adjusted incidence of CRC in the USA also increased (figure 1).
However, since this time the rates have declined an average of −1.6% per year. In the time
period 1998–2005, the rate of decline accelerated; −2.8% per year in men and −2.3% per year
in women. This reduction has been mainly confined to those of white race and is largely lim‐
ited to a decrease in the incidence of distal cancers. Although the cause of the decrease in
incidence is unknown, and may have been influenced by many factors, it is likely that much
may be attributable to screening by sigmoidoscopy and colonoscopy. In contrast, the inci‐
dence of proximal cancers has remained relatively stable over the same time period. Cur‐
rently, the overall probability of an individual developing CRC in the USA over a lifetime is
5.5% in men and 5.1% in women.
From a population perspective, age is the most important risk factor for CRC. CRC is pre‐
dominantly a disease of older individuals. 90% of cases are diagnosed over the age of 50. The
risk of CRC continues to increase with age (Figure 2). The incidence per 100,000 people age
80–84 is over seven times the incidence in people age 50–54. However, CRC can occur at any
age and the incidence of CRC occurring before age 40 may be increasing.
In the USA, the risk of CRC differs by sex. The age-adjusted incidence of CRC is over 40%
higher in men than women [8]. Overall, the incidence of CRC in men is 61 per 100,000 males
as compared to 45 per 100,000 females. In addition, the ratio of colon to rectal cancer differs
by sex; the ratio of colon to rectal cases for women is 3:1 as compared to 2:1 for males.
Race and ethnicity influence CRC risk [20]. Ashkenazi Jewish individuals appear to be at a
slightly increased risk of CRC. At least part of this increased incidence may be due to a higher
prevalence of the I1307K mutation of the adenomatous polyposis gene (APC), a mutation that
confers an increased risk of CRC development (18–30% lifetime risk). The I1307K mutation is
found in 6.1% of unselected Ashkenazi Jewish individuals and 28% of Jewish individuals with
CRC, while the mutation is rare in other populations. In the USA, the incidence of CRC is
higher in African Americans of either sex as compared to white Americans. Asian American/
Pacific Islanders, Native Americans, and Hispanic Americans experience a lower incidence of
CRC than Caucasians (Table 1).African Americans have not experienced the substantial
reduction in incidence of CRC found to have occurred in whites; prior to 1980 incidence in
African Americans was actually lower than in white Americans. In African Americans, the
increased rate of cancer is predominantly due to a higher rate of proximal cancers.
There is substantial geographic variation in the incidence of CRC, with relatively high rates in
North America, Western Europe, and Australia and relatively low rates in Africa and Asia
(Figure 3) Such observations led to Burkitt’s hypothesis; that dietary differences, specifically
fiber and fat intake, between populations were responsible for the marked variation in rates
of CRC found around the world. Burkitt observed that populations in low-risk areas of the
third world had greater stool bulk, a faster colonic transit time, and higher dietary fiber intake
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Figure 2. Age-specific SEER incidence rates in the United States 1992–2006.
White AfricanAmerican
Asian American and
Pacific Islander
American Indian/
Alaska Native
Hispanic/
Latino
Incidence Male 58.9 71.2 48.0 46.0 47.3
Female 43.2 54.5 35.4 41.2 32.8
Mortality Male 22.1 31.8 14.4 20.5 16.5
Female 15.3 22.4 10.2 14.2 10.8
*per 100,000 age-adjusted to the 2000 US standard population
Table 1. Incidence and mortality rates* for CRC by site, race and ethnicity, US 2001–2005
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than populations in high-risk, westernized regions. Although such ecological studies are
confounded by numerous factors (for example, variations in average life expectancy, cancer
detection methods, etc.), environmental factors (most prominently dietary factors) are still
considered to have a major role in this disease. This is supported by studies of migrants from
low prevalence areas to high prevalence areas. Such studies generally demonstrate that the
incidence of CRC in the migrants increases rapidly to become similar and in some cases to
exceed the incidence of the high-risk area. Interestingly, there is less variation in the incidence
of rectal cancer between countries as compared to the incidence of colon cancer.
Figure 3. A Age-Standardized (to the world population) incidence rates of cancer of the large bowel among females,
B Age-standardized (to the world population) incidence rates of cancer of the large bowel among males
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The lifetime incidence of CRC in patients at average risk is about 5 percent, with 90 percent
of cases occurring after age 50. In the US, CRC incidence is about 25 percent higher in men
than in women and is about 20 percent higher in African Americans than in whites. The inci‐
dence is higher in patients with specific inherited conditions that predispose them to the de‐
velopment of CRC.
Mortality — Death rates from CRC have declined progressively since the mid-1980s in the
United States and in many other western countries. This improvement in outcome can be
attributed, at least in part, to detection and removal of colonic polyps, detection of CRCs at
an earlier stage, and more effective treatments, particularly adjuvant therapy. Globally, the
United States has one of the highest survival rates from CRC. However, mortality rates con‐
tinue to increase in many countries with more limited resources and health infrastructure,
particularly in Central and South America and Eastern Europe [43-44]. African Americans
suffer the highest mortality rate from CRC in the USA (Table 1).The reasons for the higher
mortality rate are likely multifactorial, including the higher incidence of CRC, and the dif‐
ferences in stage distribution. Differences in incidence, stage distribution and survival of
CRC between white and African Americans are in part due to differences in socioeconomic
status, screening rates and treatment. However, the differences may also be due to genetic
and environmental factors that have yet to be elucidated. The highest mortality rates in both
sexes are estimated in Central Europe (20.3/100000 for male patients, 12.1/100000 for female
patients), and the lowest in the Middle Africa (3.5 and 2.7 respectively). The majority of
deaths of CRC occur in older people, around 80% in people aged 65 and above and almost
two-fifths of deaths appear in the group with age over 80.
Because CRC is a survivable cancer, with a 5-year survival rates adjusted for life expectan‐
cy of 64% the prevalence of people living with a diagnosis of CRC in the population is
substantial.
Factors that may have contributed to the worldwide variation in colorectal cancer incidence
patterns include differences in the prevalence of risk factors and screening practices. Estab‐
lished and suspected modifiable risk factors for colorectal cancer, including obesity, physical
inactivity, smoking, heavy alcohol consumption, a diet high in red or processed meats, and
inadequate consumption of fruits and vegetables, are also factors associated with economic
development or westernization [35].This partially explains the historically high albeit decreas‐
ing colorectal cancer incidence rates observed in long-standing developed countries such as
the United States, Canada, and New Zealand over the past several years [36]. Colorectal cancer
screening can also influence colorectal cancer incidence rates. All screening tests including
stool blood tests (e.g. fecal occult blood test) and structural screening tests (e.g. sigmoidoscopy
and colonoscopy) may increase colorectal cancer incidence rates initially as they detect
previously undiagnosed cases.
Riskfactors-Although the exact cause for the development of colorectal cancer is not known,
there are factors that increase risk for developing adenomas, polyps and cancer. These include
numerous suspect factors.
Environmental and genetic factors can increase the likelihood of developing CRC. Although
inherited susceptibility results in the most striking increases in risk, the majority of CRCs are
sporadic rather than familial. These include:
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1. HereditaryCRCsyndromes such as: Familial adenomatous polyposis (FAP) and Lynch
Syndrome (hereditary nonpolyposis colorectal cancer (HNPCC)) which are the most
common of the familial colon cancer syndromes, but together these two conditions
account for only about 5 percent of CRC cases.
a. Familialadenomatouspolyposis(FAP) and its variants (Gardner's syndrome, Turcot's
syndrome, and attenuated adenomatous polyposis coli) account for less than 1 percent of
colorectal cancers. In typical FAP, numerous colonic adenomas appear during childhood.
Symptoms appear at an average age of approximately 16 years and colonic cancer occurs
in 90 percent of untreated individuals by age 45. An attenuated form of APC (AAPC)
carries a similarly high risk of colon cancer but is characterized by fewer adenomas and
an older average age of cancer diagnosis of 54 years.
FAP is caused by germline mutations in the adenomatous polyposis coli (APC) gene which is
located on chromosome 5. The same gene is involved in the attenuated form of FAP, but the
sites of the APC gene mutations are different.
b. Lynchsyndrome — Lynch syndrome is an autosomal dominant syndrome, which is more
common than FAP, and accounts for approximately 3 to 5 percent of all colonic adeno‐
carcinomas. The name Lynch syndrome honors the pioneering work of Dr. Henry Lynch
in drawing attention to the syndrome. The term Lynch syndrome is now commonly used
for families who have been genetically determined to have a disease-causing defect in one
of the mismatch repair genes, most commonly hMLH1, hMSH2, hMSH6, or PMS2. As a
general rule, patients with Lynch syndrome have a germline mutation in one allele of a
MMR gene and the second allele is inactivated in the colorectal cancers by somatic
mutation, loss of heterozygosity, or epigenetic silencing by promoter hypermethylation.
The colorectal tumors that develop in patients with Lynch syndrome are characterized by early
age of onset and predominance of right-sided lesions [21]. The mean age at initial cancer
diagnosis is 48 years, with some patients presenting in their 20s. Nearly 70 percent of first
lesions arise proximal to the splenic flexure, and approximately 10 percent will have synchro‐
nous (simultaneous onset of two or more distinct tumors separated by normal bowel) or
metachronous cancers (non-anastomotic new tumors developing at least six months after the
initial diagnosis).
Extracolonic cancers are very common in Lynch syndrome, particularly endometrial carcino‐
ma, which may occur in up to 60 percent of female mutation carriers in some families. Other
sites at increased risk of neoplasm formation include the ovary, stomach, small bowel,
hepatobiliary system, brain and renal pelvis or ureter.
2. Personal or family history of sporadic CRCs or adenomatous polyps
Patients with a personal history of CRC or adenomatous polyps of the colon are at risk for the
future development of colon cancer. The clustering of risk in families may be attributed to an
inherited susceptibility, common environmental exposures, or a combination of both. The
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influence of a more distant family history of CRC on individual risk has not been determined
with certainty. Some of the increased risk attributed to family history is due to inheritance of
known susceptibility genes, such as mutations in the APC gene, p53 gene, or in MMR genes,
particularly MSH2, MLH1, and MSH6.
Importantly, the majority of cases of CRC cannot be attributed to known genetic defects even
when associated with a family history of CRC as recognized genetic syndromes account for
only a small proportion of all cases of CRC. Additional autosomal dominant genetic defects
conferring a high risk of CRC almost certainly is found. However, at least some of the increased
risk of CRC associated with a family history is likely attributable to other genetic factors, such
as recessive susceptibility genes, autosomal dominant genes with low penetrance, or complex
interactions between an individual’s genetic makeup and environmental factors.
Despite the importance of family history on the risk of CRC, up to 25% of individuals with a
first-degree relative with confirmed CRC do not report having such a family history and even
those that do report a history may not be aware of the increased risk associated with this. This
has important implications for the assessment of family history as well as patient and family
counseling.
3. Inflammatory bowel disease
Patients with long-standing inflammatory bowel disease (IBD) are known to be at an elevated
risk of CRC, although it is difficult to precisely estimate the risk. The magnitude of the risk has
been studied extensively in ulcerative colitis (UC).
Ulcerativecolitis— There is a well documented association between chronic ulcerative colitis
and colonic neoplasia, with the extent, duration, and activity of disease being the primary
determinants while for Crohn’s disease there are less data. However, there is an association
between pancolitis due to Crohn’s disease and the risk of colon malignancy. The extent of
disease does appear to have a significant influence on CRC risk in UC [38]. Other factors that
may modify the risk of CRC in patients with UC include the coexistence of primary sclerosing
colangitis (PSC), presence of inflammatory pseudopolyps, and severity of inflammation. For
patients with long-standing, extensive UC, colectomy is an effective strategy for the prevention
of CRC. Other strategies include endoscopic surveillance for dysplasia and/or the use of
chemopreventive agents.
The relationship between Crohn’s disease and the development of CRC has been less consis‐
tently demonstrated. In studies using data from referral-based practices, the risk of develop‐
ment of CRC appears to be significantly increased in patients with extensive Crohn’s colitis.
Finally, the risk of CRC in patients with Crohn’s disease is elevated, but the exact magnitude
of increased risk remains unclear and requires further investigation.
Several additional risk factors have been identified mostly in observational studies. These may
include: race/ethnicity and gender, acromegaly, renal transplantation, diabetes mellitus and
insulin resistance, use of androgen deprivation therapy, cholecystectomy, alcohol, obesity.
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Protectivefactors — A large number of factors have been reported by at least some studies to
be associated with a decreased risk of CRC. These include regular physical activity, a variety
of dietary factors, the regular use of aspirin or nonsteroidal antiinflammatory drugs (NSAIDs),
and hormone replacement therapy in postmenopausal women. None of these factors are
currently used to stratify CRC screening recommendations.
1. Physical Activity
Over 50 studies have been conducted to evaluate the influence of physical activity on CRC
risk. Overall, the literature is relatively consistent with respect to the effect: Greater physical
activity (occupational, recreational, or total activity) is associated with a reduced risk of CRC.
The effect is relatively small; the estimated increased risk of colon cancer in the sedentary
ranges from 1.6 to 2.0. The biological mechanisms that explain the relationship between
physical activity and CRC risk are unclear. Increased physical activity leads to changes in
insulin sensitivity and IGF levels, and both insulin and IGF are potentially involved with
colorectal carcinogenesis. Additional proposed mechanisms include effects of physical activity
on prostaglandin synthesis, effects on antitumor immune defenses, and the reduction in
percent body fat associated with exercise. The mechanism is almost certainly multifactorial.
Nonetheless, for a host of health-related reasons, frequent moderate to vigorous physical
activity can be recommended to most patients without hesitation.
2. Fruit and Vegetable Intake
The effect of dietary intake of fruit and vegetables on CRC risk has been evaluated extensively
[22]. Fruits and vegetables are a source of antioxidants, including carotenoids and ascorbate.
Other bioactive constituents in fruits and vegetables that may protect against carcinogenesis
include the indoles and isothiocyanates. The evidence for an association between fruit and
vegetable intake and the risk of CRC is inconsistent [23]. Given this, it is unlikely that a large
number of cases of CRC can be attributed directly to a lack of intake of fruits or vegetables, or
that major additional interventions to increase consumption would lead to a substantial
reduction in the incidence of CRC.
3. Aspirin and Nonsteroidal Anti-inflammatory Drugs
There is considerable observational evidence that the use of aspirin or other nonsteroidal anti-
inflammatory drugs (NSAIDs) has protective effects at all stages of colorectal carcinogenesis
(aberrant crypt foci, adenoma, carcinoma, and death from CRC [14]. The mechanism of
antineoplastic action of NSAIDs is incompletely understood, but it is believed that both
cyclooxygenase (COX)-dependent and COX-independent pathways may be involved.
NSAIDs and aspirin may play an important role in secondary chemoprevention of colorectal
adenomas and cancer. Because chemopreventive agents must be used in the general popula‐
tion to substantially reduce the burden of disease, the risks of chemoprophylaxis with aspirin
or NSAIDs may outweigh the benefits. Serious GI complications occur in regular users of
aspirin and NSAIDs although rare.
Colorectal Cancer
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4. Hormone Replacement Therapy
Observational studies have demonstrated an association between hormone replacement
therapy (HRT) in women and a reduction in both incidence and mortality from CRC. Possible
mechanisms for the effect of HRT include a reduction in bile acid secretion (a potential
promoter or initiator of CRC), as well as estrogen effects on colonic epithelium, both directly
and through alterations in insulin-like growth factor with the use of estrogens. Overall, there
appears to be a consistent reduction in the risk of CRC with the use of HRT. However, given
the potential adverse effect of HRT, this should not be used as a primary preventive strategy
for CRC.
4. Clinical presentation
4.1. Symptoms
Symptoms are common and prominent late in colon cancer when the prognosis is poor but are
less common and less obvious early in the disease. Common symptoms include abdominal
pain, rectal bleeding, altered bowel habits, and involuntary weight loss [58]. Although colon
cancer can present with either diarrhea or constipation, a recent change in bowel habits is much
more likely to be from colon cancer than chronically abnormal bowel habits. Less common
symptoms include nausea and vomiting, malaise, anorexia, and abdominal distention.
Symptoms depend on cancer location, cancer size, and presence of metastases. Left colonic
cancers are more likely than right colon cancers to cause partial or complete intestinal ob‐
struction because the left colonic lumen is narrower and the stool in the left colon tends to be
better formed because of reabsorption of water in the proximal colon [59]. Large exophytic
cancers are also more likely to obstruct the colonic lumen. Partial obstruction produces
constipation, nausea, abdominal distention, and abdominal pain. Partial obstruction occa‐
sionally paradoxically produces intermittent diarrhea as stool moves beyond the obstruction.
Distal cancers sometimes cause gross rectal bleeding, but proximal cancers rarely produce this
symptom because the blood becomes mixed with stool and chemically degraded during
colonic transit. Bleeding from proximal cancers tends to be occult, and the patient may present
with iron deficiency anemia without gross rectal bleeding. The anemia may produce weakness,
fatigue, dyspnea, or palpitations. Advanced cancer, particularly with metastasis, can cause
cancer cachexia, characterized by a symptomatic tetrad of involuntary weight loss, anorexia,
muscle weakness, and a feeling of poor health.
4.2. Signs
Just as with symptoms, colon cancer tends not to produce signs until advanced. Anemia from
gastrointestinal bleeding may produce pallor. Iron deficiency anemia can cause koilonychia
manifested by brittle, longitudinally furrowed, and spooned nails; glossitis manifested by
lingual erythema and papillae loss; and cheilitis manifested by scaling or fissuring of the lips.
Hypoalbuminemia may clinically manifest as peripheral edema, ascites, or anasarca. Hypo‐
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active or high-pitched bowel sounds suggest gastrointestinal obstruction. A palpable abdomi‐
nal mass is a rare finding that suggests advanced disease. Rectal examination, including fecal
occult blood testing (FOBT), is important in the evaluation of possible colon cancer. Rectal
cancer may be palpable by digital rectal examination. Other physical findings, although rare,
should be systematically searched for, including peripheral lymphadenopathy, especially a
Virchow’s node in the left supraclavicular space; hepatomegaly from hepatic metastases; and
temporal or intercostal muscle wasting from cancer cachexia. Very rare findings with colon
cancer include a Sister Mary Joseph node caused by metastases to a periumbilical node, and a
Blumer’s shelf caused by perirectal extension of the primary tumor.
4.3. Laboratory abnormalities
Patients with suspected colon cancer should have routine blood tests including a hemogram
with platelet count determination, serum electrolytes and glucose determination, evaluation
of routine serum biochemical parameters of liver function, and a routine coagulation profile.
About half of patients with colon cancer are anemic. Anemia, however, is very common, so
that only a small minority of patients with anemia have colon cancer. Iron deficiency anemia
of undetermined etiology, however, warrants evaluation for colon cancer, particularly in the
elderly [60]. Hypoalbuminemia is uncommon, but not rare, in colon cancer. It usually indicates
poor nutritional status from advanced cancer. Routine serum biochemical parameters of liver
function are usually within normal limits in patients with colon cancer. Abnormalities,
particularly elevation of the alkaline phosphatase level, often indicate hepatic metastases. The
serum lactate dehydrogenase level may increase with colon cancer. Diarrhea associated with
colon cancer can rarely produce electrolyte derangements or dehydration. Nausea and
vomiting from colon cancer can rarely produce metabolic derangements of hypovolemia,
hypokalemia, or alkalosis.
The serum carcinoembryonic antigen level is not useful to screen for colon cancer. It is only
moderately sensitive. Although patients with very advanced cancer tend to have highly
elevated levels, patients with early and highly curable colon cancer tend to have only mini‐
mally elevated levels, with considerable overlap with the levels of patients without colon
cancer. It is poorly specific. Other colonic diseases or systemic disorders can cause a carci‐
noembryonic antigen elevation. Preoperative testing is, however, useful to determine cancer
prognosis and to provide a baseline for comparison with postoperative levels. An elevated
serum level preoperatively is a poor prognostic indicator: the higher the serum level the more
likely the cancer is extensive and will recur postoperatively. After apparently complete colon
cancer resection the serum level almost always normalizes; failure to normalize postopera‐
tively suggests incomplete resection. A sustained and progressive rise after postoperative
normalization strongly suggests cancer recurrence. Patients with this finding require prompt
surveillance colonoscopy to exclude colonic recurrence and abdominal imaging to exclude
metastases.
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4.4. Unusual clinical syndromes caused by colon cancer
Colon cancer can cause acute colonic obstruction, most commonly from exophytic intralu‐
minal  growth,  and  most  uncommonly  from  intussusception  or  volvulus.  Obstruction
typically occurs in the sigmoid colon because of the narrow lumen and hard stool in this
region. Patients present with abdominal pain, nausea and vomiting, obstipation, abdomi‐
nal tenderness, abdominal distention, and hypoactive bowel sounds. Colon cancer can rarely
perforate acutely through the colonic wall and cause acute generalized peritonitis, and can
rarely perforate slowly to form a walled-off inflammatory mass or abscess with localized
peritoneal signs [61]. Factors promoting colonic perforation include disruption of mucosal
integrity  because  of  transmural  malignant  extension  or  colonic  ischemia,  and  increased
intraluminal  pressure  because  of  colonic  obstruction.  Presentation  with  colonic  obstruc‐
tion or perforation indicates a poor prognosis. Colon cancer rarely causes ischemic colitis
because of colonic dilatation proximal to malignant obstruction or malignant infiltration of
blood vessels.  Colon cancer  occasionally  causes  gross  rectal  bleeding because of  cancer‐
ous mucosal ulceration.
5. Colorectal cancer (crc) – screening
Colorectal cancer is theoretically a preventable disease and is ideally suited to a population
screening programme, as there is a long premalignant phase, during which there is ample
opportunity to intervene with a variety of different screening modalities.
Most CRCs are thought to arise from benign adenomatous polyps, a process that takes
approximately five to ten years. This long premalignant phase makes the disease ideally suited
to a population screening programme.
Early detection and removal of precancerous colon polyps and CRC may reduce both incidence
and death rates related of CRC. It is recommended to begin screening at age 50 for asympto‐
matic persons who are at average risk. High-risk patients should have regular colorectal
surveillance [45]. Several screening methods are used to detect CRC lesions. Colonoscopy is
the best method and final assessment step for detection of CRC.
The ultimate aim of a screening programme for CRC is to reduce mortality from the disease,
which may be achieved in two ways. As five-year survival is closely related to the stage at
which the cancer is detected (patients with Dukes’ stage A cancer have a greater than 90 per
cent five-year survival rate, while those with Dukes’ stage D disease have a 7 per cent five-
year survival rate), any screening modality that results in early detection of the disease will
have a beneficial effect on survival through more effective treatment (figure 5). Additionally,
if benign adenomatous polyps are removed, cancer development is prevented, resulting in
decreased mortality.
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Figure 4. Colorectal cancer
Figure 5. Five-year survival of colorectal cancer for each Dukes’ stage at diagnosis
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6. Who is at risk of developing colorectal cancer
There is strong tendency that countries with an obviously rising CRC incidence are more
“Westernized” in lifestyle, especially in dietary habits, with increased consumption of high fat
and protein but less fiber in diet. The change is more evident in urban areas than rural areas of
the same country. Most of CRC is sporadic, i.e., caused by the interaction of genetic and
environmental factors via the adenomacarcinoma sequence, and cancer may take up to ten years
to develop in this way. Adenomas are more common with age, and one in four of the popula‐
tion aged over 50 will develop one or more polyps, with 10% of these polyps progressing to
cancer over time.The most common indicator of high risk is a first-degree relative with CRC.
7. Tests for colorectal cancer screening
Tests for CRC include: colonoscopy, flexible sigmoidoscopy (FS), virtual colonoscopy and
faecal occult blood testing (FOBt).
7.1. Faecal Occult Blood testing (FOBt)
FOBt has been used widely in CRC screening for several decades. Screening at age 50 for
asymptomatic persons who are at average risk with annual and biennial FOBt has been shown
in multiple randomized trails to reduce CRC incidence and mortality rates [49].
FOBt can detect occult blood in a small amount of stool sample. It is cheap, non-invasive and
easily performed at home. FOBt is based on the propensity of CRC and adenomas to bleed
microscopically.
There are two different types of FOBT, guaiac FOBT (gFOBT) and immunochemical FOBT
(iFOBT). The gFOBT uses a guaiac-impregnated card to detect heme. The basis of the test
involves the detection of the peroxidase activity of heme when a hydrogen peroxide developer
is added. Therefore, the presence of any other peroxidases, e.g. from fruit/ vegetables, can
result in a false positive test, as can the presence of heme in red meat. There can also be bleeding
within the intestine for other reasons, again resulting in false positive results. False negative
results can occur due to the irregular nature of the bleeding from the tumor; several samples
are usually requested to attempt to overcome this problem [50]. The sensitivity of gFOBT is
about only 50% of cancers will be picked up in population screening (figure 6).
iFOBT test have been developed which specifically detect the hemoglobin in human feces by
antibodies and is widely available now [51]. It is more sensitive and specific for human
hemoglobin than gFOBT and thus does not require dietary or drug restriction. However,
iFOBT is more expensive than gFOBT and the high analytical sensitivity of most of the
commercially available tests results in a greater number of participants requiring colonoscopy
and a greater false positive rate [54]. However, recent developments in quantitative iFOBT
may overcome this problem, asthe trigger for investigation can be set at any concentration of
fecal hemoglobin. Clinical trials have shown that persons with positive occult-blood tests have
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a risk of cancer that is three to four times as high as that among persons with negative tests,
and that colonoscopy should be recommended for persons with these positive tests. In a recent
study (Quintero et al) it has been shown that both iFOBT and colonoscopy are effective for
detecting colorectal cancer but iFOBT is less effective for early detection of premalignant
lesions (adenomas) than colonoscopy or sigmoidoscopy [57]. However, comparative studies
have shown that iFOBT is more accurate than the gFOBT for the detection of colorectal cancer
and advanced adenomas and this new test is now recommended as the first-choice fecal occult
blood test in colorectal-cancer screening.
Figure 6. Dukes’ stage of colorectal cancers detected by faecal occult blood test screening compared to those diag‐
nosed in patients presenting with symptoms
7.2. Flexible sigmoidoscopy
Flexible sigmoidoscopy has also been used as a screening tool for CRC detection, as half of all
cancers are seen in the rectum or sigmoid colon. There have been several studies suggesting
benefit from flexible sigmoidoscopy, and their data suggest that flexible sigmoidoscopy would
be an effective screening tool. Flexible sigmoidoscopy as an alternative to colonoscopy has the
advantage that no oral bowel preparation is required, as the subject uses an enema that can be
taken at home.The procedure is quick, requires no sedation and examines the left colon, which
is the site of 75 per cent of all colorectal neoplasia. If CO2 insufflation is used, adenomas can
be resected at the initial screening examination. This procedure does not, however, examine
the right colon. For many clinicians and patients, colonoscopy is more appealing than flexible
sigmoidoscopy because patients can be sedated and undergo a complete colon examination
with polypectomy.
7.3. Virtual colonoscopy
Virtual colonoscopy, or computed tomography colonography (CTC), is another modality used
to examine the colon. It has been suggested that this examination has fewer complications and
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increased patient satisfaction when compared to colonoscopy, but with similar sensitivity and
specificity for the detection of pathology. There is no requirement for sedation and it has the
advantage of detecting extracolonic pathology. It does, however, still require bowel prepara‐
tion and colonic insufflation with CO2, the latter still causing discomfort. Furthermore, it is not
therapeutic and the lesions detected require endoscopic evaluation and resection.
7.4. Colonoscopy
Colonoscopy is the gold standard investigation for the diagnosis of CRC. It is highly sensitive
and specific for detecting both cancers and adenomas of at least 1 cm in diameter and has the
added benefit not only of providing tissue for diagnostic purposes, but also affords the
opportunity of removing adenomas by polypectomy and hence preventing colorectal cancer
(CRC). Several large cohort studies show that among patients at average risk who undergo
screening colonoscopy, 0.5 to 1.0% have colon cancer and 5 to 10% have advanced neoplasia
that can be removed. Several studies have shown that among patients with an adenoma that
is detected and removed at screening colonoscopy, colorectal cancer may develop in 0.3 to
0.9% within 3 to 5 years after screening. In a recent study (Zauber et al) it has been evaluated
the long -term effect of colonoscopic polypectomy on mortality from colorectal cancer.
According to the results of this study, the endoscopic removal of adenomas ends in reduced
mortality from colorectal cancer [56]. To sum up, this procedure is considered the most accurate
test for early detection and prevention of colorectal cancer as it markedly reduces the risk of
CRC and death. Unfortunately, there are limitations to its use as a screening modality on a
population level, although it may be the ideal choice of examination for an individual.
Colonoscopy is invasive and time consuming,and requires full bowel preparation; the
complication rate, although low, may still be unacceptable within a screening population.
Figure 7. British Society of Gastroenterology guidelines for follow-up of adenoma removal.
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8. Conclusions and recommendations
Although there are several methods available for CRC screening, none is optimal. Patients at
average risk for CRC should begin screening at age 50 with either annual FOBT, flexible
sigmoidoscopy every 5 years or colonoscopy every 10 years. Evidence does not show any
strategy as optimal, so clinicians should discuss the advantages and disadvantages of the
various screening techniques with patients. Patients with a family history of CRC or adenomas
or a personal history of high-risk polyps or inflammatory bowel disease should begin screening
earlier (figure 7). Routine screening in persons older than 75 years of age is not recommended.
Life expectancy, rather than age alone, should guide decisions about when to stop CRC
screening.
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